Highlights ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Market Closed - Nasdaq Other stock markets 21:00:00 24/06/2024 BST			5-day change	1st Jan Change
7.15 ^USD	-1.11%		-3.90%	-22.28%

06-10	Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
05-06	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	04-15	MT
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	04-15	CI
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting	04-08	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944	01-08	CI
ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology Annual Meeting	12-11	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations	21/10/23	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI
Pfizer Discloses 12% Stake in ORIC Pharmaceuticals	30/12/22	MT
Investor Caution Ahead of GDP Data, Jobless Claims Subdues Exchange-Traded Funds, Equity Futures Premarket	22/12/22	MT
Oric Pharmaceuticals Shares Soar on Pfizer's $25 Million Investment	22/12/22	DJ
ORIC Pharmaceuticals Enters Multiple Myeloma Collaboration With Pfizer; Set to Get $25 Million Equity Investment	22/12/22	MT
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer	21/12/22	CI
ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting	13/12/22	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	07/11/22	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Highlights

Filters